|
業務類別
|
Biotechnology |
|
業務概覽
|
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. |
| 公司地址
| 10224 Falls Road, Potomac, MD, USA, 20854 |
| 電話號碼
| +1 301 983-0998 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.igcinc.us |
| 員工數量
| 70 |
| Mr. Ram Mukunda |
President, Chief Executive Officer and Director |
美元 396.00K |
18/03/2026 |
| Mr. Rohit Goel |
Principal Accounting Officer |
-- |
18/03/2026 |
| Ms. Claudia Grimaldi |
Director, Vice President, Principal Financial Officer and Chief Compliance Officer |
美元 226.00K |
18/03/2026 |
|
|
| Mr. Terry L. Lierman |
Independent Director |
18/03/2026 |
| Mr. Ram Mukunda |
President, Chief Executive Officer and Director |
18/03/2026 |
| Mr. Richard Prins |
Chairman of the Board |
18/03/2026 |
| Ms. Claudia Grimaldi |
Director, Vice President, Principal Financial Officer and Chief Compliance Officer |
18/03/2026 |
| Mr. James P Moran |
Independent Director |
18/03/2026 |
|
|
|
|
